Ország: Málta
Nyelv: angol
Forrás: Medicines Authority
SODIUM IODIDE (131 I)
GE Healthcare Limited
V09FX03
SODIUM IODIDE (131 I)
CAPSULE
SODIUM IODIDE (131 I) 3.7 MBq
POM
DIAGNOSTIC RADIOPHARMACEUTICALS
Authorised
2007-04-05
PACKAGE LEAFLET: INFORMATION FOR THE USER SODIUM IODIDE ( 131 I) DIAGNOSTIC CAPSULES SODIUM IODIDE ( 131 I) DIAGNOSTIC CAPSULES 333 KBQ TO 3.7 MBQ CAPSULE SODIUM IODIDE ( 131 I) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU RECEIVE THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. IN THIS LEAFLET: 1. What Sodium Iodide ( 131 I) Diagnostic Capsules are and what they are used for 2. Before you receive Sodium Iodide ( 131 I) Diagnostic Capsules 3. How Sodium Iodide ( 131 I) Diagnostic Capsules are used 4. Possible side effects 5. How Sodium Iodide ( 131 I) Diagnostic Capsules are stored 6. Further information 1. WHAT SODIUM IODIDE ( 131 I) DIAGNOSTIC CAPSULES ARE AND WHAT THEY ARE USED FOR This medicine is for diagnostic use only. It is used only to help identify illness. Sodium Iodide ( 131 I) Diagnostic Capsules contain the active substance called sodium iodide ( 131 I). It is a radiopharmaceutical product. • It is injected into a vein by a specially trained and qualified person. • It collects in a specific organ or part of your body. • It is seen, from outside your body, by taking a scan (a picture) using special cameras. • Your doctor will explain for which particular part of your body the scan is required. • The scan can help your doctor find out more about your condition and decide on possible treatment. The scan can be used: • to help decide the treatment required for a tumour of the thyroid gland • to investigate if the treatment has successfully removed a tumour of the thyroid gland • to investigate Olvassa el a teljes dokumentumot
Page1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1 TRADE NAME OF THE MEDICINAL PRODUCT Sodium Iodide [ 131 I ] Diagnostic Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium [ 131 I ] Iodide Diagnostic Capsules are presented as a white capsule. Each capsule contains 3.7MBq (100 µCi) at the first reference date. At subsequent reference dates, at weekly intervals, the nominal activity per capsule is shown in the table below. REFERENCE DATE DAYS AFTER FIRST REFERENCE ACTIVITY –MBQ ( µCI) 1 0 3.7 (100) 2 7 2.03 (54.9) 3 14 1.11 (30.0) 4 21 0.592 (16.0) 5 28 0.333 (9.0) Iodine-131 is produced by fission of uranium-235 or by neutron bombardment of stable tellurium in a nuclear reactor. Iodine-131 has a half life of 8.04 days. It decays by emission of gamma radiations of 365KeV (81.2%), 637 KeV (7.3%) and 284 KeV (6.1%) and beta radiations of maximal energy of 606 KeV to stable Xenon 131. 3 PHARMACEUTICAL FORM Capsule. 4 CLINICAL PARTICULARS 4.1 DIAGNOSTIC INDICATIONS (1) Sodium iodide may be given as a “tracer” dose to study radioiodine kinetics. An estimation of the thyroid uptake and effective half life obtained with a tracer dose can be used to calculate the activity required for radioiodine therapy. (2) In the management of thyroid carcinoma, sodium iodide is used to identify thyroid remnants and metastases (after ablation). (3) Thyroid scanning for benign conditions with iodine-131 can be performed but only when radiopharmaceuticals with more favourable dosimetry, eg iodine-123 or technetium-99m are not available. Page2 of 12 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The recommended activities for an adult patient (70 kg) are as follows: (1) For thyroid uptake studies: 0.2 - 3.7 MBq (2) For post-thyroid ablation (for metastases and thyroid remnants): a maximum activity of 400 MBq (3) For thyroid imaging: 7.4 - 11 MBq Scans are usually Olvassa el a teljes dokumentumot